Vivek Subbiah: AACR Cancer Progress Report 2024
Vivek Subbiah shared a post on LinkedIn:
“Happy Friday, everyone!
-Finally getting a chance to dive into the AACR Cancer Progress Report 2024 American Association for Cancer Research AACR Journals
-We are truly living in unprecedented times, with amazing advancements in cancer research happening all around us
-The science is nothing short of inspiring, fueling progress and revolutionizing cancer care.
-Let’s continue to support and celebrate the incredible work being done to bring us closer to a world without cancer.”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023